Search

Your search keyword '"Åsberg, Anders"' showing total 914 results
Start Over Author "Åsberg, Anders"
914 results on '"Åsberg, Anders"'

151. The ERA-EDTA Registry Annual Report 2017

Author

Kramer, Anneke, Boenink, Rianne, Noordzij, Marlies, Bosdriesz, Jizzo R., Stel, Vianda S., Beltrán, Palma, Ruiz, Juan C., Seyahi, Nurhan, Comas Farnés, Jordi, Stendahl, Maria, Garneata, Liliana, Winzeler, Rebecca, Golan, Eliezer, Lopot, František, Korejwo, Grzegorz, Bonthuis, Marjolein, Lassalle, Mathilde, Slon Roblero, María F., Kuzema, Viktorija, Hommel, Kristine, Stojceva-Taneva, Olivera, Åsberg, Anders, Kramar, Reinhard, Hemmelder, Marc H., de Meester, Johan, Vazelov, Evgueniy, Andrusev, Anton M., Castro de la Nuez, Pablo, Helve, Jaakko, Komissarov, Kirill, Casula, Anna, Magaz, Ángela, Santiuste de Pablos, Carmen, Bubic, Ivan, Traynor, Jamie P., Ioannou, Kyriakos, Idrizi, Alma, Palsson, Runolfur, des Grottes, Jean-Marin, Spustova, Viera, Tolaj-Avdiu, Miloreta, Nordio, Maurizio, Ziginskiene, Edita, Massy, Ziad A., Jager, Kitty J., APH - Quality of Care, APH - Aging & Later Life, ACS - Pulmonary hypertension & thrombosis, Medical Informatics, Graduate School, Infectious diseases, APH - Methodology, APH - Health Behaviors & Chronic Diseases, Amsterdam Gastroenterology Endocrinology Metabolism, and APH - Global Health

Published
2020

155. The ERA-EDTA Registry Annual Report 2018: a summary

Author

Kramer, Anneke, primary, Boenink, Rianne, additional, Stel, Vianda S, additional, Santiuste de Pablos, Carmen, additional, Tomović, Filip, additional, Golan, Eliezer, additional, Kerschbaum, Julia, additional, Seyahi, Nurhan, additional, Ioanou, Kyriakos, additional, Beltrán, Palma, additional, Zurriaga, Oscar, additional, Magaz, Ángela, additional, Slon Roblero, María F, additional, Gjorgjievski, Nikola, additional, Garneata, Liliana, additional, Arribas, Federico, additional, Galvão, Ana A, additional, Bell, Samira, additional, Ots-Rosenberg, Mai, additional, Muñoz-Terol, José M, additional, Winzeler, Rebecca, additional, Hommel, Kristine, additional, Åsberg, Anders, additional, Spustova, Viera, additional, Palencia García, María Ángeles, additional, Vazelov, Evgueniy, additional, Finne, Patrik, additional, ten Dam, Marc A G J, additional, Lopot, František, additional, Trujillo-Alemán, Sara, additional, Lassalle, Mathilde, additional, Kolesnyk, Mykola O, additional, Santhakumaran, Shalini, additional, Idrizi, Alma, additional, Andrusev, Anton, additional, Comas Farnés, Jordi, additional, Komissarov, Kirill, additional, Resić, Halima, additional, Palsson, Runolfur, additional, Kuzema, Viktorija, additional, Garcia Bazaga, Maria Angeles, additional, Ziginskiene, Edita, additional, Stendahl, Maria, additional, Bonthuis, Marjolein, additional, Massy, Ziad A, additional, and Jager, Kitty J, additional

Published
2020
Full Text
View/download PDF

156. Recovery of kidney function in patients treated with maintenance dialysis—a report from the ERA-EDTA Registry

Author

Jakulj, Lily, primary, Kramer, Anneke, additional, Åsberg, Anders, additional, de Meester, Johan, additional, Santiuste de Pablos, Carmen, additional, Helve, Jaakko, additional, Hemmelder, Marc H, additional, Hertig, Alexandre, additional, Arici, Mustafa, additional, Bell, Samira, additional, Mercadal, Lucile, additional, Diaz-Corte, Carmen, additional, Palsson, Runolfur, additional, Benitez Sanchez, Manuel, additional, Kerschbaum, Julia, additional, Collart, Frederic, additional, Massy, Ziad A, additional, Jager, Kitty J, additional, and Noordzij, Marlies, additional

Published
2020
Full Text
View/download PDF

162. ERA Registry Annual Report 2019: summary and age comparisons.

Author

Boenink, Rianne, Astley, Megan E, Huijben, Jilske A, Stel, Vianda S, Kerschbaum, Julia, Ots-Rosenberg, Mai, Åsberg, Anders A, Lopot, Frantisek, Golan, Eliezer, Nuez, Pablo Castro de la, Camblor, Marta Rodríguez, Trujillo-Alemán, Sara, Millan, Juan Carlos Ruiz San, Mingo, Pablo Ucio, Díaz, Juan Manuel, Bouzas-Caamaño, M Encarnación, Artamendi, Marta, Madre, Manuel I Aparicio, Pablos, Carmen Santiuste de, and Roblero, María Fernanda Slon

Subjects
CORPORATION reports, RENAL replacement therapy, CHRONIC kidney failure, KIDNEY transplantation, PERITONEAL dialysis
Abstract

Background Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. Methods Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. Results In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p. with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010–14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

163. Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response.

Author

Stillemans, Gabriel, Paquot, Adrien, Muccioli, Giulio G., Hoste, Emilia, Panin, Nadtha, Åsberg, Anders, Balligand, Jean‐Luc, Haufroid, Vincent, and Elens, Laure

Subjects
SINGLE nucleotide polymorphisms, ATORVASTATIN, PHARMACOKINETICS, DRUG efficacy, GENETIC polymorphisms, TREATMENT effectiveness, LDL cholesterol
Abstract

The purpose of this study was to investigate the potential clinical relevance of estimating the apparent clearance (CL/F) of atorvastatin through population pharmacokinetic (PopPK) modeling with samples collected in a real‐life setting in a cohort of ambulatory patients at risk of cardiovascular disease by using an opportunistic sampling strategy easily accessible in clinical routine. A total of 132 pharmacokinetic (PK) samples at a maximum of three visits were collected in the 70 included patients. The effects of demographic, genetic, and clinical covariates were also considered. With the collected data, we developed a two‐compartment PopPK model that allowed estimating atorvastatin CL/F relatively precisely and considering the genotype of the patient for SLCO1B1 c.521T>C single‐nucleotide polymorphism (SNP). Our results indicate that the estimation of the CL/F of atorvastatin through our PopPK model might help in identifying patients at risk of myalgia. Indeed, we showed that a patient presenting a CL/F lower than 414.67 L h−1 is at risk of suffering from muscle discomfort. We also observed that the CL/F was correlated with the efficacy outcomes, suggesting that a higher CL/F is associated with a better drug efficacy (i.e., a greater decrease in total and LDL‐cholesterol levels). In conclusion, our study demonstrates that PopPK modeling can be useful in daily clinics to estimate a patient' atorvastatin clearance. Notifying the clinician with this information can help in identifying patients at risk of myalgia and gives indication about the potential responsiveness to atorvastatin therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

165. Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial.

Author

Kvitne, Kine Eide, Robertsen, Ida, Skovlund, Eva, Christensen, Hege, Krogstad, Veronica, Wegler, Christine, Angeles, Philip Carlo, Wollmann, Birgit Malene, Hole, Kristine, Johnson, Line Kristin, Sandbu, Rune, Artursson, Per, Karlsson, Cecilia, Andersson, Shalini, Andersson, Tommy B., Hjelmesæth, Jøran, Jansson‐Löfmark, Rasmus, and Åsberg, Anders

Subjects
WEIGHT loss, GASTRIC bypass, BODY weight, MORBID obesity, LOW-calorie diet, MIDAZOLAM, BIOAVAILABILITY
Abstract

It remains uncertain whether pharmacokinetic changes following Roux‐en‐Y gastric bypass (RYGB) can be attributed to surgery‐induced gastrointestinal alterations per se and/or the subsequent weight loss. The aim was to compare short‐ and long‐term effects of RYGB and calorie restriction on CYP3A‐activity, and cross‐sectionally compare CYP3A‐activity with normal weight to overweight controls using midazolam as probe drug. This three‐armed controlled trial included patients with severe obesity preparing for RYGB (n = 41) or diet‐induced (n = 41) weight‐loss, and controls (n = 18). Both weight‐loss groups underwent a 3‐week low‐energy‐diet (<1200 kcal/day) followed by a 6‐week very‐low‐energy‐diet or RYGB (both <800 kcal/day). Patients were followed for 2 years, with four pharmacokinetic investigations using semisimultaneous oral and intravenous dosing to determine changes in midazolam absolute bioavailability and clearance, within and between groups. The RYGB and diet groups showed similar weight‐loss at week 9 (13 ± 2.4% vs. 11 ± 3.6%), but differed substantially after 2 years (−30 ± 7.0% vs. −3.1 ± 6.3%). At baseline, mean absolute bioavailability and clearance of midazolam were similar in the RYGB and diet groups, but higher compared with controls. On average, absolute bioavailability was unaltered at week 9, but decreased by 40 ± 7.5% in the RYGB group and 32 ± 6.1% in the diet group at year 2 compared with baseline, with no between‐group difference. No difference in clearance was observed over time, nor between groups. In conclusion, neither RYGB per se nor weight loss impacted absolute bioavailability or clearance of midazolam short term. Long term, absolute bioavailability was similarly decreased in both groups despite different weight loss, suggesting that the recovered CYP3A‐activity is not only dependent on weight‐loss through RYGB. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

170. A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease

Author

Luis-Lima, Sergio, primary, Mas-Sanmartin, Carolina, additional, Rodríguez-Rodríguez, Ana Elena, additional, Porrini, Esteban, additional, Ortiz, Alberto, additional, Gaspari, Flavio, additional, Diaz-Martin, Laura, additional, Åsberg, Anders, additional, Jenssen, Trond, additional, Jiménez-Sosa, Alejandro, additional, Martinez-Ros, Paula, additional, and Gonzalez-Bulnes, Antonio, additional

Published
2020
Full Text
View/download PDF

181. Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study

Author

Blom, Kjersti Benedicte, primary, Bergo, Kaja Knudsen, additional, Espe, Emil Knut Stenersen, additional, Rosseland, Vigdis, additional, Grøtta, Ole Jørgen, additional, Mjøen, Geir, additional, Åsberg, Anders, additional, Bergan, Stein, additional, Sanner, Helga, additional, Bergersen, Tone Kristin, additional, Bjørnerheim, Reidar, additional, Skauby, Morten, additional, Seljeflot, Ingebjørg, additional, Waldum-Grevbo, Bård, additional, Dahle, Dag Olav, additional, Sjaastad, Ivar, additional, and Birkeland, Jon Arne, additional

Published
2019
Full Text
View/download PDF

182. A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity

Author

Krogstad, Veronica, primary, Peric, Alexandra, additional, Robertsen, Ida, additional, Kringen, Marianne K., additional, Wegler, Christine, additional, Angeles, Philip Carlo, additional, Hjelmesæth, Jøran, additional, Karlsson, Cecilia, additional, Andersson, Shalini, additional, Artursson, Per, additional, Åsberg, Anders, additional, Andersson, Tommy B., additional, and Christensen, Hege, additional

Published
2019
Full Text
View/download PDF

183. 242.2: Similar 1-year organ function from controlled donation after circulatory death using normo-thermic regional perfusion and donation after brain death.

Author

Foss, Stein, primary, Nordheim, Espen, additional, Hagness, Morten, additional, Sørensen, Dag Wendelbo, additional, Syversen, Torgunn Bø, additional, Midtvedt, Karsten, additional, Åsberg, Anders, additional, Dahl, Thorleif, additional, Storrø, Monika Olofsson, additional, Fiane, Arnt Espen, additional, and Line, Pal-Dag, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results